Duodenal pulsENDO as an Early Treatment for Type 2 DM
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorChinese University of Hong Kong
About this trial
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).
Eligibility criteria
Qualifiers
Duration of T2DM </= 2 years
HbA1c </= 7.5%
On 0-1 oral diabetes medications
Disqualifiers
Previous treatment with pulsENDO or similar procedure
Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO
Type I DM, DM secondary to specific disease or having any history of ketoacidosis
Fasting C-peptide level <0.5ug/L
Trial design
Treatments tested in this trial
- pulsENDO treatment
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
1Chinese University of Hong Kong Shatin Hong Kong
Sponsors and collaborators
Chinese University of Hong Kong
Lead sponsor
Source ClinicalTrials.gov